ImmuCell Corporation (ICCC): Price and Financial Metrics
ICCC Stock Summary
- ICCC has a higher market value than only 13.14% of US stocks; more precisely, its current market capitalization is $78,981,463.
- ICCC's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 228.99 -- higher than 84.83% of US-listed equities with positive expected earnings growth.
- The price/operating cash flow metric for Immucell Corp is higher than 92.96% of stocks in our set with a positive cash flow.
- Stocks with similar financial metrics, market capitalization, and price volatility to Immucell Corp are OIIM, MOSY, KMDA, SLRX, and INTZ.
- ICCC's SEC filings can be seen here. And to visit Immucell Corp's official web site, go to immucell.com.
ICCC Stock Price Chart Interactive Chart >
ICCC Price/Volume Stats
| Current price | $10.95 | 52-week high | $13.20 |
| Prev. close | $11.43 | 52-week low | $3.70 |
| Day low | $10.88 | Volume | 21,700 |
| Day high | $11.49 | Avg. volume | 69,285 |
| 50-day MA | $8.45 | Dividend yield | N/A |
| 200-day MA | $6.14 | Market Cap | 78.98M |
ImmuCell Corporation (ICCC) Company Bio
ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.
Latest ICCC News From Around the Web
Below are the latest news stories about Immucell Corp that investors may wish to consider to help them evaluate ICCC as an investment opportunity.
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q4 2020 Results - Earnings Call TranscriptImmuCell Corporation (ICCC) Q4 2020 Earnings Conference Call February 23, 2021 09:00 A.M. ET Company Participants Joe Diaz - Lytham Partners Michael F. Brigham - President and CEO Conference Call Participants Sam Rebotsky - SER Asset Management George Melas-Kyriazi - MKH Management Unidentified Analyst - Private Investor Louis Parks -... |
ImmuCell Corp. to Host Earnings CallNEW YORK, NY / ACCESSWIRE / February 23, 2021 / ImmuCell Corp. (NASDAQ:ICCC) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 23, 2021 at 9:00 AM Eastern Time. |
ImmuCell EPS beats by $0.10, beats on revenueImmuCell (ICCC): FY GAAP EPS of -$0.14 beats by $0.10.Revenue of $15.3M beats by $0.16M.Press Release... |
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2020Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ETPORTLAND, Maine, Feb. 16, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, will report unaudited financial results for the year ended December 31, 2020 after the market closes on Monday, February 22, 2021. The Company has scheduled a conference call the next morning, Tuesday, February 23, 2021, at 9:00 AM ET to review the results. Interested parties can access the conference call scheduled by the Company to review the full year 2020 financial results by dialing (844) 855-9502 (toll free) or (412... |
The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPOHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 27) Abbott Laboratories (NYSE: ABT ) (reacted to fourth-quarter results) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Aziyo Biologics Inc (NASDAQ: AZYO ) Cassava Sciences Inc (NASDAQ: SAVA ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Frequency Therapeutics Inc (NASDAQ: FREQ ) (reacted to ratings upgrade by JPMorgan to Overweight) Fulgent Genetics Inc (NASDAQ: FLGT ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc. (NASDAQ: ILMN ) ImmuCell Corporation (NASDAQ: ICCC ) I... |
ICCC Price Returns
| 1-mo | 9.94% |
| 3-mo | 89.82% |
| 6-mo | 105.97% |
| 1-year | 115.13% |
| 3-year | 50.00% |
| 5-year | 76.90% |
| YTD | 84.03% |
| 2020 | 15.53% |
| 2019 | -26.95% |
| 2018 | -19.80% |
| 2017 | 47.73% |
| 2016 | N/A |
Continue Researching ICCC
Want to see what other sources are saying about Immucell Corp's financials and stock price? Try the links below:Immucell Corp (ICCC) Stock Price | Nasdaq
Immucell Corp (ICCC) Stock Quote, History and News - Yahoo Finance
Immucell Corp (ICCC) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...